SCHEMBL4084784

SCHEMBL4084784

CCOC(=O)c1c(N)sc2c1CCCN2C(=O)OC(C)(C)C

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA1 P30542 6/20 0.61
ALDH1A1 P00352 11/20 0.53
MAPT P10636 10/20 0.53
HPGD P15428 9/20 0.53
GAA P10253 8/20 0.53
KDM4E B2RXH2 4/20 0.53
HSD17B10 Q99714 3/20 0.53
ALOX15 P16050 2/20 0.53
MAPK1 P28482 1/20 0.53
MEN1 O00255 5/20 0.51
KMT2A Q03164 5/20 0.51
POLB P06746 2/20 0.51
RECQL P46063 1/20 0.51
RXFP1 Q9HBX9 1/20 0.51
TDP1 Q9NUW8 1/20 0.51
L3MBTL1 Q9Y468 1/20 0.51
TSHR P16473 2/20 0.46
ALOX12 P18054 1/20 0.46
SMN1; SMN2 Q16637 3/20 0.45
LMNA P02545 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27418736 0.81 MAPT (0.51) ADORA1ALDH1A1MAPTHPGDGAA
SCHEMBL939860 0.81 ADORA1 (0.88) ADORA1ALDH1A1MAPTHPGDGAA
SCHEMBL27418742 0.78 ALDH1A1 (0.46) ALDH1A1MAPTHPGDKDM4EHSD17B10
SCHEMBL27414983 0.76 ALDH1A1 (0.42) ADORA1ALDH1A1MAPTHPGDGAA
SCHEMBL937489 0.76 ADORA1 (0.85) ADORA1ALDH1A1MAPTHPGDGAA
SCHEMBL27077204 0.76 ADORA1 (0.61) ADORA1ALDH1A1MAPTHPGDGAA
SCHEMBL14408979 0.76 MAPT (0.43) ADORA1ALDH1A1MAPTHPGDGAA
SCHEMBL938730 0.76 ADORA1 (0.84) ADORA1ALDH1A1MAPTHPGDGAA
SCHEMBL938054 0.76 ADORA1 (1.00) ADORA1ALDH1A1MAPTHPGDGAA
SCHEMBL4086756 0.74 CNR2 (0.52) ADORA1ALDH1A1MAPTHPGDKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12018021-B2 Thiophene derivatives for the treatment of disorders caused by IgE UCB Biopharma SRL (BE) 2024-06-25 US disclosed
US-12018021-B2 Thiophene derivatives for the treatment of disorders caused by IgE UCB Biopharma SRL (BE) 2024-06-25 US disclosed
US-20220332709-A1 Thiophene derivatives for the treatment of disorders caused by IgE UCB Biopharma SRL (BE) 2022-10-20 US disclosed
CN-112566910-A Thiophene derivatives for the treatment of IgE induced diseases UCB生物制药有限责任公司 2021-03-26 CN disclosed
US-8338623-B2 N-{3-[(2,5-dimethylmorpholin-4-yl)carbonyl]-4,7-dihydro-5H-thieno[2,3-c]pyran-2-yl}hexahydro-2,5-methanopentalene-3a(1H)-carboxamide; CB2 receptors ligand; antiinflammatory, analgesic agent; autoimmune diseases; neuroprotectants ABBVIE INC. (US) 2012-12-25 US disclosed
US-20090018114-A1 NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS ABBOTT LABORATORIES (US) 2009-01-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220332709-A1 Thiophene derivatives for the treatment of disorders caused by IgE TSLP, CYSLTR1, CYSLTR2 ADORA1 1519/4885ALDH1A1 233/4885MAPT 2356/4885
US-12018021-B2 Thiophene derivatives for the treatment of disorders caused by IgE TSLP, CYSLTR1, CYSLTR2 ADORA1 1519/4885ALDH1A1 233/4885MAPT 2356/4885
US-20090018114-A1 NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS CNR1, CNR2, GPR18 ADORA1 364/4885ALDH1A1 1504/4885MAPT 2527/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.